Literature DB >> 2003714

Cardiopulmonary toxicity after liposomal amphotericin B infusion.

S J Levine1, T J Walsh, A Martinez, P Q Eichacker, G Lopez-Berestein, C Natanson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2003714     DOI： 10.7326/0003-4819-114-8-664

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  14 in total

Review 1.  A persistent challenge: the diagnosis of respiratory disease in the non-AIDS immunocompromised host.

Authors:  C Mayaud; J Cadranel
Journal:  Thorax       Date:  2000-06       Impact factor: 9.139

2.  Interferon-associated left ventricular dysfunction in a liver transplant recipient.

Authors:  R Mateo; S Jethmalani; D C Angus; J Gorcsan; B Uretsky; J Fung
Journal:  Dig Dis Sci       Date:  1996-07       Impact factor: 3.199

3.  Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.

Authors:  J D Berman; R Badaro; C P Thakur; K M Wasunna; K Behbehani; R Davidson; F Kuzoe; L Pang; K Weerasuriya; A D Bryceson
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

4.  Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.

Authors:  T J Walsh; P Whitcomb; S Piscitelli; W D Figg; S Hill; S J Chanock; P Jarosinski; R Gupta; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

5.  Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.

Authors:  Nita L Seibel; Aziza T Shad; Ihor Bekersky; Andreas H Groll; Corina Gonzalez; Lauren V Wood; Paul Jarosinski; Donald Buell; William W Hope; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

6.  Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia.

Authors:  M Arning; A H Heer-Sonderhoff; A Wehmeier; W Schneider
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-01       Impact factor: 3.267

7.  Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity.

Authors:  A van 't Veen; D Gommers; J W Mouton; J A Kluytmans; E J Krijt; B Lachmann
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

Review 8.  Adverse drug events related to dosage forms and delivery systems.

Authors:  I F Uchegbu; A T Florence
Journal:  Drug Saf       Date:  1996-01       Impact factor: 5.606

9.  Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients.

Authors:  T J Walsh; V Yeldandi; M McEvoy; C Gonzalez; S Chanock; A Freifeld; N I Seibel; P O Whitcomb; P Jarosinski; G Boswell; I Bekersky; A Alak; D Buell; J Barret; W Wilson
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

10.  Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles.

Authors:  J Brajtburg; S Elberg; S J Travis; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.